publication date: Jun. 2, 2017

In Brief CancerLinQ partners with FDA to study real-world use of newly approved cancer treatments

CancerLinQ LLC, an initiative of the American Society of Clinical Oncology, announced a long-term partnership with FDA that will rely on cancer patient information and big data analytics to examine the real-world use of emerging and newly approved cancer therapies.

Real-world data from will be used to grow the knowledge base about patterns of care across all cancer types and therapies, accelerate development of novel insights that might otherwise be challenging to obtain through standard research initiatives and data collection means.

Under the partnership, FDA and CancerLinQ will use CancerLinQ Discovery, a research and analytics platform that allows users to analyze real-world, aggregated, de-identified patient care data from oncology practices that participate in the CancerLinQ data-sharing program. The CancerLinQ network currently includes a growing number of patient records from nearly 90 oncology practices and institutions, making it among the largest and most robust sources of real-world evidence in oncology. 

“This collaboration addresses one of oncology’s central challenges – to quickly learn about the real-world impact of cancer therapies once a drug is approved,” said Clifford Hudis, CEO of ASCO and chairman of the CancerLinQ board of governors. “Until now, our learning about new treatments was hindered by the limited number of physicians and … Continue reading CancerLinQ partners with FDA to study real-world use of newly approved cancer treatments

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.